MYC Is Amplified in BRCA1-Associated Breast Cancers

Tatyana A. Grushko, James J. Dignam, Soma Das, Anne M. Blackwood, Charles M. Perou, Karin K. Ridderstråle, Kristin N. Anderson, Min Jie Wei, April J. Adams, Fitsum G. Hagos, Lise Sveen, Henry T. Lynch, Barbara L. Weber, Olufunmilayo I. Olopade

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Purpose: Germ-line mutations in the BRCA1 tumor suppressor gene predispose to early onset breast cancers with a distinct phenotype characterized by high tumor grade, aneuploidy, high proliferation rate, and estrogen receptor-negativity. The molecular mechanisms and cooperative oncogenes contributing to multistep tumor progression in cells lacking BRCA1 are not well defined. To examine whether C-MYC (MYC), a transforming oncogene associated with genetic instability, contributes to multistep tumor progression in BRCA1-associated breast cancer, we have analyzed tumors from women with hereditary BRCA1-mutated and sporadic breast cancers. Experimental Design: We performed fluorescence in situ hybridization using a MYC:CEP8 assay on formalin-fixed paraffin-embedded tumor tissues from 40 women with known deleterious germ-line BRCA1 mutations and 62 sporadic cases, including 20 cases with hypermethylation of the BRCA1 gene promoter. Results: We observed a MYC:CEP8 amplification ratio ≥2 in 21 of 40 (53%) BRCA1-mutated tumors compared with 14 of 62 (23%) sporadic tumors (P = 0.003). Of the 14 sporadic cases with MYC amplification, 8 (57%) were BRCA1-methylated. In total, MYC amplification was found in a significantly higher proportion of tumors with BRCA1 dysfunction (29 of 60, 48% versus 6 of 42, 14%; P = 0.0003). In a multivariable regression model controlling for age, tumor size, and estrogen receptor status, BRCA1-mutated tumors demonstrated significantly greater mean MYC:CEP8 ratio than sporadic tumors (P = 0.02). Conclusions: Our data indicate that MYC oncogene amplification contributes to tumor progression in BRCA1-associated breast cancers. Thus, we conclude that the aggressive histopathological features of BRCA1-associated tumors are in part due to dysregulated MYC activity.

Original languageEnglish
Pages (from-to)499-507
Number of pages9
JournalClinical Cancer Research
Volume10
Issue number2
DOIs
StatePublished - Jan 15 2004

Fingerprint

Breast Neoplasms
Neoplasms
Oncogenes
Germ-Line Mutation
Estrogen Receptors
BRCA1 Gene
Aneuploidy
Tumor Suppressor Genes
Fluorescence In Situ Hybridization
Paraffin
Formaldehyde
Research Design
Phenotype

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Grushko, T. A., Dignam, J. J., Das, S., Blackwood, A. M., Perou, C. M., Ridderstråle, K. K., ... Olopade, O. I. (2004). MYC Is Amplified in BRCA1-Associated Breast Cancers. Clinical Cancer Research, 10(2), 499-507. https://doi.org/10.1158/1078-0432.CCR-0976-03

MYC Is Amplified in BRCA1-Associated Breast Cancers. / Grushko, Tatyana A.; Dignam, James J.; Das, Soma; Blackwood, Anne M.; Perou, Charles M.; Ridderstråle, Karin K.; Anderson, Kristin N.; Wei, Min Jie; Adams, April J.; Hagos, Fitsum G.; Sveen, Lise; Lynch, Henry T.; Weber, Barbara L.; Olopade, Olufunmilayo I.

In: Clinical Cancer Research, Vol. 10, No. 2, 15.01.2004, p. 499-507.

Research output: Contribution to journalArticle

Grushko, TA, Dignam, JJ, Das, S, Blackwood, AM, Perou, CM, Ridderstråle, KK, Anderson, KN, Wei, MJ, Adams, AJ, Hagos, FG, Sveen, L, Lynch, HT, Weber, BL & Olopade, OI 2004, 'MYC Is Amplified in BRCA1-Associated Breast Cancers', Clinical Cancer Research, vol. 10, no. 2, pp. 499-507. https://doi.org/10.1158/1078-0432.CCR-0976-03
Grushko TA, Dignam JJ, Das S, Blackwood AM, Perou CM, Ridderstråle KK et al. MYC Is Amplified in BRCA1-Associated Breast Cancers. Clinical Cancer Research. 2004 Jan 15;10(2):499-507. https://doi.org/10.1158/1078-0432.CCR-0976-03
Grushko, Tatyana A. ; Dignam, James J. ; Das, Soma ; Blackwood, Anne M. ; Perou, Charles M. ; Ridderstråle, Karin K. ; Anderson, Kristin N. ; Wei, Min Jie ; Adams, April J. ; Hagos, Fitsum G. ; Sveen, Lise ; Lynch, Henry T. ; Weber, Barbara L. ; Olopade, Olufunmilayo I. / MYC Is Amplified in BRCA1-Associated Breast Cancers. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 2. pp. 499-507.
@article{30de95d7405f4682b9d0bac933e6599e,
title = "MYC Is Amplified in BRCA1-Associated Breast Cancers",
abstract = "Purpose: Germ-line mutations in the BRCA1 tumor suppressor gene predispose to early onset breast cancers with a distinct phenotype characterized by high tumor grade, aneuploidy, high proliferation rate, and estrogen receptor-negativity. The molecular mechanisms and cooperative oncogenes contributing to multistep tumor progression in cells lacking BRCA1 are not well defined. To examine whether C-MYC (MYC), a transforming oncogene associated with genetic instability, contributes to multistep tumor progression in BRCA1-associated breast cancer, we have analyzed tumors from women with hereditary BRCA1-mutated and sporadic breast cancers. Experimental Design: We performed fluorescence in situ hybridization using a MYC:CEP8 assay on formalin-fixed paraffin-embedded tumor tissues from 40 women with known deleterious germ-line BRCA1 mutations and 62 sporadic cases, including 20 cases with hypermethylation of the BRCA1 gene promoter. Results: We observed a MYC:CEP8 amplification ratio ≥2 in 21 of 40 (53{\%}) BRCA1-mutated tumors compared with 14 of 62 (23{\%}) sporadic tumors (P = 0.003). Of the 14 sporadic cases with MYC amplification, 8 (57{\%}) were BRCA1-methylated. In total, MYC amplification was found in a significantly higher proportion of tumors with BRCA1 dysfunction (29 of 60, 48{\%} versus 6 of 42, 14{\%}; P = 0.0003). In a multivariable regression model controlling for age, tumor size, and estrogen receptor status, BRCA1-mutated tumors demonstrated significantly greater mean MYC:CEP8 ratio than sporadic tumors (P = 0.02). Conclusions: Our data indicate that MYC oncogene amplification contributes to tumor progression in BRCA1-associated breast cancers. Thus, we conclude that the aggressive histopathological features of BRCA1-associated tumors are in part due to dysregulated MYC activity.",
author = "Grushko, {Tatyana A.} and Dignam, {James J.} and Soma Das and Blackwood, {Anne M.} and Perou, {Charles M.} and Ridderstr{\aa}le, {Karin K.} and Anderson, {Kristin N.} and Wei, {Min Jie} and Adams, {April J.} and Hagos, {Fitsum G.} and Lise Sveen and Lynch, {Henry T.} and Weber, {Barbara L.} and Olopade, {Olufunmilayo I.}",
year = "2004",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-0976-03",
language = "English",
volume = "10",
pages = "499--507",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - MYC Is Amplified in BRCA1-Associated Breast Cancers

AU - Grushko, Tatyana A.

AU - Dignam, James J.

AU - Das, Soma

AU - Blackwood, Anne M.

AU - Perou, Charles M.

AU - Ridderstråle, Karin K.

AU - Anderson, Kristin N.

AU - Wei, Min Jie

AU - Adams, April J.

AU - Hagos, Fitsum G.

AU - Sveen, Lise

AU - Lynch, Henry T.

AU - Weber, Barbara L.

AU - Olopade, Olufunmilayo I.

PY - 2004/1/15

Y1 - 2004/1/15

N2 - Purpose: Germ-line mutations in the BRCA1 tumor suppressor gene predispose to early onset breast cancers with a distinct phenotype characterized by high tumor grade, aneuploidy, high proliferation rate, and estrogen receptor-negativity. The molecular mechanisms and cooperative oncogenes contributing to multistep tumor progression in cells lacking BRCA1 are not well defined. To examine whether C-MYC (MYC), a transforming oncogene associated with genetic instability, contributes to multistep tumor progression in BRCA1-associated breast cancer, we have analyzed tumors from women with hereditary BRCA1-mutated and sporadic breast cancers. Experimental Design: We performed fluorescence in situ hybridization using a MYC:CEP8 assay on formalin-fixed paraffin-embedded tumor tissues from 40 women with known deleterious germ-line BRCA1 mutations and 62 sporadic cases, including 20 cases with hypermethylation of the BRCA1 gene promoter. Results: We observed a MYC:CEP8 amplification ratio ≥2 in 21 of 40 (53%) BRCA1-mutated tumors compared with 14 of 62 (23%) sporadic tumors (P = 0.003). Of the 14 sporadic cases with MYC amplification, 8 (57%) were BRCA1-methylated. In total, MYC amplification was found in a significantly higher proportion of tumors with BRCA1 dysfunction (29 of 60, 48% versus 6 of 42, 14%; P = 0.0003). In a multivariable regression model controlling for age, tumor size, and estrogen receptor status, BRCA1-mutated tumors demonstrated significantly greater mean MYC:CEP8 ratio than sporadic tumors (P = 0.02). Conclusions: Our data indicate that MYC oncogene amplification contributes to tumor progression in BRCA1-associated breast cancers. Thus, we conclude that the aggressive histopathological features of BRCA1-associated tumors are in part due to dysregulated MYC activity.

AB - Purpose: Germ-line mutations in the BRCA1 tumor suppressor gene predispose to early onset breast cancers with a distinct phenotype characterized by high tumor grade, aneuploidy, high proliferation rate, and estrogen receptor-negativity. The molecular mechanisms and cooperative oncogenes contributing to multistep tumor progression in cells lacking BRCA1 are not well defined. To examine whether C-MYC (MYC), a transforming oncogene associated with genetic instability, contributes to multistep tumor progression in BRCA1-associated breast cancer, we have analyzed tumors from women with hereditary BRCA1-mutated and sporadic breast cancers. Experimental Design: We performed fluorescence in situ hybridization using a MYC:CEP8 assay on formalin-fixed paraffin-embedded tumor tissues from 40 women with known deleterious germ-line BRCA1 mutations and 62 sporadic cases, including 20 cases with hypermethylation of the BRCA1 gene promoter. Results: We observed a MYC:CEP8 amplification ratio ≥2 in 21 of 40 (53%) BRCA1-mutated tumors compared with 14 of 62 (23%) sporadic tumors (P = 0.003). Of the 14 sporadic cases with MYC amplification, 8 (57%) were BRCA1-methylated. In total, MYC amplification was found in a significantly higher proportion of tumors with BRCA1 dysfunction (29 of 60, 48% versus 6 of 42, 14%; P = 0.0003). In a multivariable regression model controlling for age, tumor size, and estrogen receptor status, BRCA1-mutated tumors demonstrated significantly greater mean MYC:CEP8 ratio than sporadic tumors (P = 0.02). Conclusions: Our data indicate that MYC oncogene amplification contributes to tumor progression in BRCA1-associated breast cancers. Thus, we conclude that the aggressive histopathological features of BRCA1-associated tumors are in part due to dysregulated MYC activity.

UR - http://www.scopus.com/inward/record.url?scp=10744222271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744222271&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-0976-03

DO - 10.1158/1078-0432.CCR-0976-03

M3 - Article

VL - 10

SP - 499

EP - 507

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -